As such, we sought to interrogate the consequences of Setd2 inactivation in KRAS-driven lung adenocarcinoma in order to better understand how SETD2 deficiency drives early and widespread tumor growth and identify intrinsic therapeutic vulnerabilities that may exist. The gene discussed is KRAS; the disease is neoplasm.